HER2 overexpression renders human breast cancers sensitive to PARP inhibition

['lizbeth]

or a Sugar Mama! BTW . . . I believe Dr. O’Shaughnessy is a female, as in Joyce. I remember her because she said:

TCH/pertuzumab may become the standard toward the end of the year.

She was discussing that the:

TRYPHAENA trial showed similar pCR rates of about 60% to 70% when patients were assigned preoperatively to TCH with pertuzumab versus FEC followed by taxane/trastuzumab/pertuzumab.

Maybe we need to get the ball rolling on social media - "Battle of the Bands" sounds a lot more appealing to me than the stink of Pink!